BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 35226309)

  • 21. Immune checkpoint inhibitors in NSCLC.
    Johnson DB; Rioth MJ; Horn L
    Curr Treat Options Oncol; 2014 Dec; 15(4):658-69. PubMed ID: 25096781
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Clinical Development of Immunotherapy for Small Cell Lung Cancer].
    Yu T; Zhong D
    Zhongguo Fei Ai Za Zhi; 2018 Dec; 21(12):918-923. PubMed ID: 30591100
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunotherapy versus standard chemotherapy for treatment of extensive-stage small-cell lung cancer: a systematic review.
    Liu X; Xing H; Zhang H; Liu H; Chen J
    Immunotherapy; 2021 Aug; 13(12):989-1000. PubMed ID: 34114477
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Emerging drugs for small cell lung cancer: a focused review on immune checkpoint inhibitors.
    Reddy HG; Qin A; Kalemkerian GP
    Expert Opin Emerg Drugs; 2020 Sep; 25(3):353-366. PubMed ID: 32683991
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Personalized Therapy of Small Cell Lung Cancer.
    Schneider BJ; Kalemkerian GP
    Adv Exp Med Biol; 2016; 890():149-74. PubMed ID: 26703804
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune Checkpoint Inhibitors and Chemoradiation for Limited-Stage Small Cell Lung Cancer.
    Schlick B; Shields MD; Marin-Acevedo JA; Patel I; Pellini B
    Curr Treat Options Oncol; 2022 Aug; 23(8):1104-1120. PubMed ID: 35716328
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Immunotherapy Advances in Small Cell Lung Cancer].
    Xu Y; Zhan P; Song Y
    Zhongguo Fei Ai Za Zhi; 2020 Nov; 23(11):989-998. PubMed ID: 32752583
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunotherapy for Advanced Lung Cancer.
    Asmar R; Rizvi NA
    Cancer J; 2015; 21(5):383-91. PubMed ID: 26389763
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunotherapy in Lung Cancer.
    Castellanos EH; Horn L
    Cancer Treat Res; 2016; 170():203-23. PubMed ID: 27535396
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune Checkpoint Inhibitors in Small Cell Lung Cancer: A Partially Realized Potential.
    Armstrong SA; Liu SV
    Adv Ther; 2019 Aug; 36(8):1826-1832. PubMed ID: 31209697
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current and future therapeutic approaches for the treatment of small cell lung cancer.
    Rossi A; Tay R; Chiramel J; Prelaj A; Califano R
    Expert Rev Anticancer Ther; 2018 May; 18(5):473-486. PubMed ID: 29544351
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The evolving landscape of immunotherapy in small-cell lung cancer: A focus on predictive biomarkers.
    Gelsomino F; Lamberti G; Parisi C; Casolari L; Melotti B; Sperandi F; Ardizzoni A
    Cancer Treat Rev; 2019 Sep; 79():101887. PubMed ID: 31491661
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of Immunotherapy in Extensive-Stage Small Cell Lung Cancer.
    Konala VM; Madhira BR; Ashraf S; Graziano S
    Oncology; 2020; 98(11):749-754. PubMed ID: 32663833
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Small cell lung cancer: Novel treatments beyond immunotherapy.
    Meijer JJ; Leonetti A; Airò G; Tiseo M; Rolfo C; Giovannetti E; Vahabi M
    Semin Cancer Biol; 2022 Nov; 86(Pt 2):376-385. PubMed ID: 35568295
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune checkpoint inhibitors in small cell lung cancer.
    Pakkala S; Owonikoko TK
    J Thorac Dis; 2018 Feb; 10(Suppl 3):S460-S467. PubMed ID: 29593891
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel immunotherapy in the treatment of advanced non-small cell lung cancer.
    Santabarbara G; Maione P; Rossi A; Palazzolo G; Gridelli C
    Expert Rev Clin Pharmacol; 2016 Dec; 9(12):1571-1581. PubMed ID: 27623999
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeted Therapy and Immune Therapy for Small Cell Lung Cancer.
    Gadgeel SM
    Curr Treat Options Oncol; 2018 Sep; 19(11):53. PubMed ID: 30203184
    [TBL] [Abstract][Full Text] [Related]  

  • 38. What Are the Biomarkers for Immunotherapy in SCLC?
    Longo V; Catino A; Montrone M; Pizzutilo P; Annese T; Pesola F; Marech I; Cassiano S; Ribatti D; Galetta D
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681779
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways.
    Rouanne M; Roumiguié M; Houédé N; Masson-Lecomte A; Colin P; Pignot G; Larré S; Xylinas E; Rouprêt M; Neuzillet Y
    World J Urol; 2018 Nov; 36(11):1727-1740. PubMed ID: 29855698
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune checkpoint inhibitors for nonsmall cell lung cancer treatment.
    Chen YM
    J Chin Med Assoc; 2017 Jan; 80(1):7-14. PubMed ID: 27693088
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.